Using positron emission tomography to assess tumor proliferation in non-Hodgkin lymphoma

References

• Weber G. Enzymology of cancer cells (first of two parts). N Engl J Med 1977;296:486–492.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029–1033.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13–20.
   PubMed Web of Science ®Google Scholar
• Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002;40:2–11.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Tomita N, Takeuchi K, et al SUVmax in FDG-PET at the biopsy site correlates with the proliferaiton potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma 2009; 51:279–283.
   Web of Science ®Google Scholar
• Okada J, Yoshikawa K, Itami M, et al Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325–329.
   PubMed Web of Science ®Google Scholar
• Lapela M, Leskinen S, Minn HR, et al Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522–3527.
   PubMed Web of Science ®Google Scholar
• Schoder H, Noy A, Gonen M, et al Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643–4651.
   PubMed Web of Science ®Google Scholar
• Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 2009;84:338–343.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790–1796.
   PubMed Web of Science ®Google Scholar
• Wong CY, Thie J, Parling-Lynch KJ, et al Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas. J Nucl Med 2005;46:1659–1663.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Stein H, Pileri S, et al Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 1987;2:448–449.
   PubMed Web of Science ®Google Scholar
• Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfeld AG. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988;154:223–235.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma – a Nordic Lymphoma Group study. Ann Hematol 2004;83:414–419.
   PubMed Web of Science ®Google Scholar
• Miller TP, Grogan TM, Dahlberg S, et al Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994;83:1460–1466.
   PubMed Web of Science ®Google Scholar
• Grogan TM, Lippman SM, Spier CM, et al Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988;71:1157–1160.
   PubMed Web of Science ®Google Scholar
• Yamanaka N, Harabuchi Y, Kataura A. The prognostic value of Ki-67 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity. Cancer 1992;70:2342–2349.
   PubMed Web of Science ®Google Scholar
• Winter JN, Andersen J, Variakojis D, et al Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. Blood 1996;88:3919–3925.
   PubMed Web of Science ®Google Scholar
• Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002;69:11–20.
   PubMed Web of Science ®Google Scholar
• Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008;142:149–165.
   PubMed Web of Science ®Google Scholar
• Karam M, Ata A, Irish K, et al FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Commun 2009;30:770–778.
   PubMed Web of Science ®Google Scholar
• Bodet-Milin C, Kraeber-Bodere F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 2008;93:471–472.
   PubMed Web of Science ®Google Scholar
• Noy A, Schoder H, Gonen M, et al The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009;20:508–512.
   PubMed Web of Science ®Google Scholar
• Hicks RJ. The SUV and FLT PET: a tasty alphabet soup or a dog's breakfast? Leuk Lymphoma 2007;48:649–652.
   PubMed Web of Science ®Google Scholar
• Tang B, Malysz J, Douglas-Nikitin V, et al Correlating metabolic activity with cellular proliferation in follicular lymphomas. Mol Imaging Biol 2009;11:296–302.
   PubMed Web of Science ®Google Scholar
• Buck AK, Bommer M, Stilgenbauer S, et al Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006;66:11055–11061.
   PubMed Web of Science ®Google Scholar
• Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 2008;29:521–526.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Wiseman GA, Vose JM, et al Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652–4661.
   PubMed Web of Science ®Google Scholar